See every side of every news story
Published loading...Updated

Lupin and Avas launch NaMuscla in Italy - Express Pharma

Summary by Express Pharma
Lupin and Avas Pharmaceuticals SRL announced the launch of Lupin’s orphan drug NaMuscla (mexiletine) in Italy. Avas will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.  NDM disorders are a group of rare, inherited neuromuscular disorders which is characterised by the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in people wi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Lupin broke the news in on Tuesday, January 28, 2025.
Sources are mostly out of (0)